Elthera AG is a Swiss biopharmaceutical brand that is dedicated to revolutionizing oncology treatment through the development of proprietary, first-in-class drugs. With a personalized healthcare approach, Elthera AG aims to improve the lives of patients with the most aggressive malignancies. The brand is focused on developing antibodies against L1CAM, a novel target that is strongly associated with aggressive tumor phenotypes and poor prognosis in various types of cancer.

By combining targeted anti-L1CAM therapy with companion diagnostics, Elthera AG is pioneering the creation of personalized treatments that can significantly enhance survival rates. Led by a management team with over 50 years of combined experience in biologics development, Elthera AG has an in-depth understanding of the entire drug development process. Their expertise spans from discovery to clinical proof-of-concept and beyond, ensuring the highest level of quality and efficacy in their products.

With their groundbreaking approach and commitment to innovation, Elthera AG is at the forefront of advancing oncology treatments and bringing hope to patients worldwide